Aura Biosciences logo
Aura Biosciences
AURA | NASDAQ
Chart Builder DCF Calculator
$7.22
+$0.11 (+1.55%)
At close: Nov 16, 2026, 4:00 PM ET
$7.22
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Aura Biosciences Company Profile

Company profile explained

Company Profile

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Key Executives

Name Position
Natalie C. Holles President, CEO & Director
Julie Person Chief People Officer
Susan Abu-Absi Chief Operating Officer
Alex Dasalla Head of Investor Relations & Corporate Communications
Amy Elazzouzi Senior Vice President of Finance, Treasurer and Secretary
Anthony Daniels Vice President & Therapeutic Area of Head Ocular Oncology
Erica Kratz Chief Regulatory & Quality Officer
Jill Hopkins Chief Medical Officer & President of Research and Development
Patrick Nealon Senior Vice President of Clinical Development Operations

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 01, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 S-8 Filing
Aug 20, 2026 EFFECT Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Aura Biosciences
Aura Biosciences logo
Country United States
IPO Date Oct 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 113
CEO Natalie C. Holles

Contact Details

85 Bolton Street Boston, Massachusetts 02135 United States

Stock Details

Ticker Symbol AURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501796
CUSIP Number 05153U107
ISIN Number US05153U1079
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.